VYT Stock Overview

Develops, produces, and sells active ingredients from plant stem cells for the cosmetic sector primarily in Spain. More details

VYT fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 45.2% below our estimate of its fair value

Earnings have grown 28.3% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (€17M)

Shareholders have been diluted in the past year

My Notes

Capture your thoughts, links and company narrative

Vytrus Biotech, S.A. Competitors

Mauritius Cosmetics

MUSE:MCOS.I0000

MU₨845.0m

Kolinpharma

BIT:KIP

€15.9m

Gillette Pakistan

KASE:GLPL

PK₨5.1b

Nippon Shikizai

TSE:4920

JP¥2.5b

Price History & Performance

Summary of share price highs, lows and changes for Vytrus Biotech
Historical stock prices
Current Share Price	€2.20
52 Week High	€2.60
52 Week Low	€1.78
Beta	-0.0032
1 Month Change	-0.90%
3 Month Change	-4.35%
1 Year Change	15.79%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.85%

Recent updates

Pinning Down Vytrus Biotech, S.A.'s (BME:VYT) P/E Is Difficult Right Now

Sep 26

Shareholder Returns

	VYT	ES Personal Products	ES Market
7D	0%	-1.6%	-2.2%
1Y	15.8%	-7.2%	10.7%

Return vs Industry: VYT exceeded the Spanish Personal Products industry which returned -6.8% over the past year.

Return vs Market: VYT exceeded the Spanish Market which returned 12.3% over the past year.

Price Volatility

Is VYT's price volatile compared to industry and market?
VYT volatility
VYT Average Weekly Movement	2.5%
Personal Products Industry Average Movement	3.8%
Market Average Movement	3.2%
10% most volatile stocks in ES Market	5.7%
10% least volatile stocks in ES Market	0.6%

Stable Share Price: VYT has not had significant price volatility in the past 3 months compared to the Spanish market.

Volatility Over Time: VYT's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2009	35	Albert Font	www.vytrus.com

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells for the cosmetic sector primarily in Spain. It offers Nectaria Lithops, an active ingredient that biophysically optimizes the skin microenvironment and vitamin D levels; Photobiome a microbiota photoprotector; Olea Vitae cellular oil for ageing; Turmeria Zen for skin hydration and wrinkles on stressed profiles; Sensia Carota, a plant-based active that protects and prevents from the damage on sensitive and sensitized skins; Deobiome Noni, a biological deodorant; and Sarcoslim Re-Shape to reduce fat on tissue. The company also offers Capilia Longa for hair growth reactivation; Luminia Granatum for skin brightening;Elaya Renova a hair tensegrist; Kannabia Sense that stimulates the microbiota-skin-brain axis; Quora Noni to avoid the attack of skin harmful bacteria; Quora Noni biomics for rejuvenating the skin microbiota; Centella Reversa for facial complexion improvement; and Arabian Cotton for protection against photo-ageing.

Vytrus Biotech, S.A. Fundamentals Summary

How do Vytrus Biotech's earnings and revenue compare to its market cap?
VYT fundamental statistics
Market cap	€16.59m
Earnings (TTM)	€696.78k
Revenue (TTM)	€5.24m

23.8x

P/E Ratio

3.2x

P/S Ratio

Is VYT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VYT income statement (TTM)
Revenue	€5.24m
Cost of Revenue	€491.63k
Gross Profit	€4.75m
Other Expenses	€4.05m
Earnings	€696.78k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.092
Gross Margin	90.61%
Net Profit Margin	13.30%
Debt/Equity Ratio	29.8%

How did VYT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 05:58
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vytrus Biotech, S.A. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Marisa Luisa Mazo Fajardo	GVC Gaesco Valores